NR1I3 and diabetes mellitus: Evodiamine and rutaecarpine can inhibit gluconeogenesis and adipogenesis by activating constitutive androstane receptor (CAR) in vitro and in vivo and have therapeutic potential for the treatment of hyperglycemia and diabetes mellitus type 2 (Yu et al., 2016).